- ETST
partners with Iq2 to develop food supplement designed to improve brain
function
- Clinched
deal with Forzagen to distribute cannabinoid product line in Mexico and
South America
- Developing
CBD beverage to tap $12 billion market
Earth Science Tech Inc. (OTCQB: ETST) has done it again. In
partnership with Iq2 Labs, the Florida-based biotechnology company is
formulating a super food supplement designed to enhance brain function through
an initiative that continues the ongoing drive to strengthen its position in
the hemp-derived cannabinoid, nutraceutical, pharmaceutical and medical device
markets (http://ibn.fm/802tg).
The product, containing high-grade full-spectrum cannabinoids, is currently
going through the package design process, after which it will be bottled,
launched and plugged into ETST’s growing sales channels. The announcement
by ETST comes on the heels of another: ETST has clinched a deal with premium
dietary supplement provider Forzagen to distribute ETST’s line of cannabinoids
throughout Mexico and South America (http://ibn.fm/HZAKY).
The partnership with Iq2 Labs and the introduction of the
brain-boosting supplement – CBD Mental Clarity and Focus Shot – give ETST a
foothold in the emerging CBD beverage market, according to Nickolas S. Tabraue,
chairman of ETST. The high-grade full-spectrum cannabinoids produced in
conjunction with Iq2 are expected to be an accretive addition to ETST’s line of
products aiming to augment mental capacity and function. The company’s
researchers continue their efforts to develop a CBD beverage utilizing the University
of Central Oklahoma’s provisional patent to improve immune system
functions (http://ibn.fm/KiZ40).
An aspect of ETST’s marketing strategy focuses on increasing the ways it can
deliver its CBD products to the marketplace. The collaboration with the
University of Central Oklahoma, under the direction of Dr. Michel Aube, chief
science officer of ETST, forms part of this plan.
Under a sponsored research agreement with the University of
Central Oklahoma, tests were carried out to determine the effects of ETST’s CBD
Cannabidiol Rich Hemp Oil on immune cells. The results were
encouraging (http://ibn.fm/MwRi8).
Research showed that ETST’s hemp oil solution, used in appropriate CBD
concentrations, could, through the production of Tumor Necrosis Factor alpha
(TNFα), stimulate macrophages, an important immune cell. The cytokine TNFα is a
key cell signaler in the recruitment of immune cells. A robust immune system plays
an important part in maintaining good health and may help fight cancer. There
is now hope that the effects of hemp oil enriched with CBD on immune cells may
be used to improve cancer treatment, particularly in combination with other
treatment modalities. The proposed beverage will allow ETST to tap into the
$11.7 billion (2018 estimate) CBD beverage market, which is projected to hit
$25 billion by 2025.
With the establishment of these partnerships in 2019, ETST
sustains the relentless path of growth put into place in 2018, when it doubled
sales. ETST also uplisted to the OTCQB Venture Market and introduced a new
product, Hygee, a non-invasive discreet chlamydia testing kit. The company
continues to disrupt the hemp-derived cannabinoid, nutraceutical, pharmaceutical
and medical device markets. Its activities range from R&D to production to
marketing and distribution. ETST plans to keep building the networks and
infrastructure to launch new subsidiaries and new products, like its super
supplement to boost brainpower.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
